Table of Contents Table of Contents
Previous Page  114 / 812 Next Page
Information
Show Menu
Previous Page 114 / 812 Next Page
Page Background

S110

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

Introduction

Dysregulation of the apoptotic process is associ-

ated with the etiopathogenesis of schizophrenia, which is observed

at the brain and peripheral blood levels. A significant nega-

tive correlation between the duration of the disease and serum

sFasL concentration was demonstrated by other authors. It was

shown that an increased rate of apoptosis is more pronounced in

neuroleptic-free patients with the first-episode of schizophrenia

than in patients with chronic disease.

Aim

Search for a predictor of good response to antipsychotic

treatment based on the analysis of the sFasL plasma level and its

relationship with clinical symptoms.

Methods

Fifty-three patients with chronic schizophrenia and 46

healthy individualswere enrolled in the study. The concentration of

sFasL was measured by ELISA. Clinical assessments (PANSS, SANS,

SAPS) and blood analyses were conducted three times: during the

active phase of disease (at admission), after 4 weeks of pharma-

cotherapy, and after reaching remission.

Results

In the schizophrenia group, non-altered levels of sFasL

(

P

= 0.1; U Mann-Whitney test), compared to the control, were

detected at admission. The initial level of sFasL correlated nega-

tively (

r

=

0.33;

P

= 0.04; Spearman’s rank) with blood leukocyte

count. Despite clinical improvement, no significant changes in the

level of sFasL were observed. However, the sFasL level correlated

negatively with the PANSS general psychopathology reduction

after 4 weeks of pharmacotherapy (

r

=

0.7;

P

= 0.04) and after

remission (

r

=

0.39;

P

= 0.026).

Conclusions

The results indicate a possible role of sFasL in apo-

ptosis of blood leukocytes and suggest that the reduction of sFasL

level can predict level of PANSS general psychopathology after

antipsychotic treatment in schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.096

FC93

Basic symptoms as subjective

cognitive deficit in schizophrenia:

Cognitive, clinical and functional

associations

M.L. Vargas

1 ,

, S. López-Lorenzo

2

, I. Legascue

2

, A. Nagore

2

,

P. Serrano

2

, N. Jimeno-Bulnes

3

1

Complejo Asistencial de Segovia, Grupo de Investigación en

Neurociencia Clínica de Segovia GINCS, Psychiatry, Segovia, Spain

2

Grupo de Investigación en Neurociencia Clínica de Segovia GINCS,

Psychiatry, Segovia, Spain

3

Universidad de Valladolid, Grupo de Investigación en Neurociencia

Clínica de Segovia GINCS, Psychiatry, Segovia, Spain

Corresponding author.

Introduction

Basic symptoms are subjective complaints that

present at the early states in psychotic disorders and persist in the

long-term. They can be studied using hetero applied clinical instru-

ments or self-administered questionnaires. Basic symptoms can be

useful as screening tools in at risk populations.

Aims

To determine if basic symptoms (subjective cognitive

deficits) are associated with the objectively measured cognitive

deficit after controlling for functioning and symptomatology.

Methods

One observational, transversal, psychopathological and

neuropsychological study was performed on a schizophrenia out-

patients sample (

n

= 78). Correlations were measured by using

Spearman’s Rho coefficient. Basic symptoms were registered by

using the Frankfurt Complaints Questionnaire (FCQ-3); cognitive

status was assessed by Repeatable Battery for the Assessment of

Neuropsychological Status (RBANS); clinical status was assessed

by PANSS and Clinical Global Impression (CGI); functional status

was measured with Global Assessment of Functioning (GAF).

Results

All the dimensionswere related to subjective complaints:

cognitive functioning (

r

=

.38;

P

< .001); positive symptoms

(

r

= .54;

P

< .001); negative symptoms (

r

= .26;

P

< .02); general

symptoms (

r

= .41;

P

< .001); CGI (

r

= .57;

P

< .001); GAF (

r

=

.45;

P

< .001). The association between subjective and objective cogni-

tive deficit remains significative after controlling for the clinical and

functional variables, except when controlling for CGI.

Conclusions

The evaluation of basic symptoms with FCQ-3 is

related with an objective cognitive deficit and could be useful as

a screening tool.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.097

FC94

Adjunctive memantine in

clozapine-treated refractory

schizophrenia: A one-year extension

study

S. Veerman

1 ,

, P. Schulte

2

, J.B. Deijen

3

, L. de Haan

4

1

Mental Health Service Organisation North Holland North,

Community Mental Health Division, Flexible Assertive Community

Treatment, Alkmaar, Netherlands

2

Mental Health Service Organisation North Holland North, Division

for Specialised Treatment, Treatment Centre for Bipolar Disorders,

Alkmaar, Netherlands

3

VU Medical Center, Psychology, Amsterdam, Netherlands

4

Academic Medical Center, University of Amsterdam, Academic

Psychiatric Centre, Early Psychosis Department, Arkin, Amsterdam,

Netherlands

Corresponding author.

Introduction

In a recent 26-week placebo-controlled, crossover

trial (

n

= 52) we found significant positive effects on verbal and

visual memory, and negative symptoms in clozapine-treated

patients with refractory schizophrenia.

Objectives

In this 1-year extension study, we report the long-

term effects and tolerability of memantine add-on therapy to

clozapine.

Aims

To evaluate the persistence of improvements in cognitive

functioning and symptoms of memantine add-on therapy to cloza-

pine in schizophrenia.

Methods

Completers of the first trial who experienced a bene-

ficial effect of memantine after 12 weeks continued memantine

for one year. Primary endpoints were change from baseline to 26

weeks treatment and 26 weeks to 52 weeks treatment on memory

and executive function using the Cambridge Neuropsychological

Test Automated Battery (CANTAB), Positive andNegative Syndrome

Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-

S). Secondary endpoints were change on the Health of the Nation

Outcome Scales (HoNOS) and Liverpool University Neuroleptic Side

Effect Rating Scale (LUNSERS).

Results

Of 32 completers who experienced a beneficial effect

of memantine 23 patients continued memantine for one year.

Memory improvement was sustained, verbal recognition mem-

ory improved even further between

t

= 26 weeks and

t

= 52 weeks.

Continued treatment with memantine add-on to clozapine was

associated with significantly improved PANSS positive, negative

and overall score, CGI-S and HoNOS scores.

Conclusions

In the extension phase the positive effect of

memantine add-on therapy on verbal memory sustained and pos-

itive, negative and overall symptoms of schizophrenia, clinical

global status and psychosocial functioning significantly improved.

Memantine was well tolerated without serious adverse effects.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.098